#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Laura Johnson Email
Chief Scientific Officer . Verismo Therapeutics
How to contact Laura Johnson
Join and see Laura's contact info for free!Current Roles
Employees:
31Revenue:
$2.4MAbout
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.Verismo Therapeutics Address
3675 Market StPhiladelphia, PA
United States